Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Kendra C. Foley"'
Autor:
Kendra C. Foley, Timothy T. Spear, David C. Murray, Kaoru Nagato, Elizabeth Garrett-Mayer, Michael I. Nishimura
Publikováno v:
Molecular Therapy: Oncolytics, Vol 5, Iss C, Pp 105-115 (2017)
T cell receptor (TCR)-gene-modified T cells for adoptive cell transfer can mediate objective clinical responses in melanoma and other malignancies. When introducing a second TCR, mispairing between the endogenous and introduced α and β TCR chains l
Externí odkaz:
https://doaj.org/article/3189595fbbd7476cb5193f7c6d87a5a8
Autor:
Grant L.J. Keller, Jesus A. Alonso, Timothy P. Riley, Kendra C. Foley, Nishant K. Singh, Brian M. Baker, Lance M. Hellman, Craig W. Vander Kooi, Cory M. Ayres, Michael I. Nishimura, Jason R. Devlin, Yuting Zhang
Publikováno v:
Molecular Therapy. 27:300-313
T cell receptors (TCRs) have emerged as a new class of immunological therapeutics. However, though antigen specificity is a hallmark of adaptive immunity, TCRs themselves do not possess the high specificity of monoclonal antibodies. Although a necess
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9a7a37434c6ee2c7a776772482ea1ddf
https://doi.org/10.1016/j.ymthe.2018.12.010
https://doi.org/10.1016/j.ymthe.2018.12.010
Autor:
Marvin H. Gee, Timothy P. Riley, Brian M. Baker, Kendra C. Foley, K. Christopher Garcia, Craig W. Vander Kooi, Lance M. Hellman, Juan L. Mendoza, Jesus A. Alonso, Michael I. Nishimura
Publikováno v:
Nature chemical biology
T cell receptor cross-reactivity allows a fixed T cell repertoire to respond to a much larger universe of potential antigens. Recent work has emphasized the importance of peptide structural and chemical homology, as opposed to sequence similarity, in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b79c97dc8a1063f3fe2446d5e2a7e1d5
https://doi.org/10.1038/s41589-018-0130-4
https://doi.org/10.1038/s41589-018-0130-4
Autor:
Jared L. Dietze, Daniel A. Rothenberg, Terri A. Addona, Antoine Boudot, Jessica Kohler, Jennifer G. Abelin, Vikram R. Juneja, Paul J. Turcott, Brandon P. Conn, Marit M. van Buuren, Scott P. Goulding, Christopher D. McGann, Richard B. Gaynor, John R. Srouji, Kendra C. Foley, Jae Won Choi, Michael S. Rooney, Divya Lenkala
Publikováno v:
Cell Reports Methods. 1:100084
Summary Oncogenic mutations in KRAS can be recognized by T cells on specific class I human leukocyte antigen (HLA-I) molecules, leading to tumor control. To date, the discovery of T cell targets from KRAS mutations has relied on occasional T cell res
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6c80a975d5d541b12214cf886b5d9702
https://doi.org/10.1016/j.crmeth.2021.100084
https://doi.org/10.1016/j.crmeth.2021.100084
Autor:
David C. Murray, Timothy T. Spear, Kaoru Nagato, Elizabeth Garrett-Mayer, Kendra C. Foley, Michael I. Nishimura
Publikováno v:
Molecular Therapy: Oncolytics, Vol 5, Iss C, Pp 105-115 (2017)
Molecular Therapy Oncolytics
Molecular Therapy Oncolytics
T cell receptor (TCR)-gene-modified T cells for adoptive cell transfer can mediate objective clinical responses in melanoma and other malignancies. When introducing a second TCR, mispairing between the endogenous and introduced α and β TCR chains l
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e89352bf46cedeb64ea83602f8ab2487
https://doi.org/10.1016/j.omto.2017.05.004
https://doi.org/10.1016/j.omto.2017.05.004
Autor:
Elizabeth Garrett-Mayer, Jeffrey J. Roszkowski, Glenda G. Callender, Timothy T. Spear, Michael I. Nishimura, Makio Iwashima, Yuan Wang, Patricia E. Simms, Kendra C. Foley, Lance M. Hellman, Rachel H. McMahan, Brian M. Baker, Gina Scurti, Timothy P. Riley, Gretchen E. Lyons, Hugo R. Rosen, David C. Murray
Publikováno v:
Journal of Leukocyte Biology. 100:545-557
A major obstacle hindering the development of effective immunity against viral infections, their associated disease, and certain cancers is their inherent genomic instability. Accumulation of mutations can alter processing and presentation of antigen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6d7812bd4b032ab30b8988a27394e7b2
https://doi.org/10.1189/jlb.2a1215-561r
https://doi.org/10.1189/jlb.2a1215-561r
Autor:
Jeffrey J. Roszkowski, Michael I. Nishimura, Kendra C. Foley, Glenda G. Callender, Alexander Langerman, Timothy T. Spear, Mingli Li, Elizabeth Garrett-Mayer, Yi Zhang, Gina Scurti, Patricia E. Simms, David C. Murray, Justin T. Thomas, Kelly Moxley
Publikováno v:
Cancer Immunology, Immunotherapy. 65:293-304
The success in recent clinical trials using T cell receptor (TCR)-genetically engineered T cells to treat melanoma has encouraged the use of this approach toward other malignancies and viral infections. Although hepatitis C virus (HCV) infection is b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dfb9458df968e5d83db209213dfbe4c8
https://doi.org/10.1007/s00262-016-1800-2
https://doi.org/10.1007/s00262-016-1800-2
Publikováno v:
Melanoma research. 28(3)
Immunotherapy is a promising method of treatment for a number of cancers. Many of the curative results have been seen specifically in advanced-stage melanoma. Despite this, single-agent therapies are only successful in a small percentage of patients,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ba49e9c28fe6a09dd2c4324e9b589b31
https://pubmed.ncbi.nlm.nih.gov/29521881
https://pubmed.ncbi.nlm.nih.gov/29521881
T cell receptor (TCR) gene-modified T cells are a promising immunotherapy but require refinement to improve clinical responses and limit off-target toxicities. A variety of TCR and gene-delivery vector modifications have been developed to enhance int
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5b6d651875af5c887045185a91160f31
https://europepmc.org/articles/PMC6133711/
https://europepmc.org/articles/PMC6133711/
Autor:
Kendra C. Foley, Timothy T. Spear, Yuan Wang, Patricia E. Simms, Michael I. Nishimura, David C. Murray, Gina Scurti, Lance M. Hellman, Elizabeth Garrett-Mayer, Brian M. Baker
Publikováno v:
Cancer immunology, immunotherapy : CII. 66(11)
T-cell receptor (TCR)-pMHC affinity has been generally accepted to be the most important factor dictating antigen recognition in gene-modified T-cells. As such, there is great interest in optimizing TCR-based immunotherapies by enhancing TCR affinity
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::545468a290b7bf095d80814f8f6e02f0
https://pubmed.ncbi.nlm.nih.gov/28634816
https://pubmed.ncbi.nlm.nih.gov/28634816